BACKGROUND: In patients with advanced gastroesophageal cancer, the phase iii Randomized ECF for Advanced and Locally Advanced Esophagogastric Cancer 2 (real-2) trial demonstrated equivalent clinical efficacy when capecitabine (x) was substituted for 5-fluorouracil (5fu) in the epirubicin-cisplatin-5fu (ecf) regimen. The present analysis compares the direct medical costs associated with both regimens. METHODS: This cost-consequence analysis of direct medical costs took resource utilization data from the real-2 trial where available. Direct medical costs were derived from the perspective of the Canadian public health care system in 2008 Canadian dollars. Mean cost per patient on each treatment arm was calculated. RESULTS: Drug costs from start of treatment until first progression, including pre- and post-chemotherapy medications and administration costs, totalled $5,344 for ecx as compared with $3,187 for ecf. Costs for treatment of adverse events were estimated at $2,621 for ecx as compared with $3,397 for ecf. An additional cost of $873 was associated with insertion of an implanted venous access. Total incremental cost of ecx over ecf was $508. CONCLUSIONS: In advanced gastroesophageal cancer, capecitabine is an attractive alternative to 5fu. Although the drug cost per se is greater, use of capecitabine is associated with decreased consumption of hospital resources. Not only does capecitabine fit with patient preference for oral therapy, it also avoids the inconvenience and complications of central venous access.
RCT Entities:
BACKGROUND: In patients with advanced gastroesophageal cancer, the phase iii Randomized ECF for Advanced and Locally Advanced Esophagogastric Cancer 2 (real-2) trial demonstrated equivalent clinical efficacy when capecitabine (x) was substituted for 5-fluorouracil (5fu) in the epirubicin-cisplatin-5fu (ecf) regimen. The present analysis compares the direct medical costs associated with both regimens. METHODS: This cost-consequence analysis of direct medical costs took resource utilization data from the real-2 trial where available. Direct medical costs were derived from the perspective of the Canadian public health care system in 2008 Canadian dollars. Mean cost per patient on each treatment arm was calculated. RESULTS: Drug costs from start of treatment until first progression, including pre- and post-chemotherapy medications and administration costs, totalled $5,344 for ecx as compared with $3,187 for ecf. Costs for treatment of adverse events were estimated at $2,621 for ecx as compared with $3,397 for ecf. An additional cost of $873 was associated with insertion of an implanted venous access. Total incremental cost of ecx over ecf was $508. CONCLUSIONS: In advanced gastroesophageal cancer, capecitabine is an attractive alternative to 5fu. Although the drug cost per se is greater, use of capecitabine is associated with decreased consumption of hospital resources. Not only does capecitabine fit with patient preference for oral therapy, it also avoids the inconvenience and complications of central venous access.
Authors: P Ross; M Nicolson; D Cunningham; J Valle; M Seymour; P Harper; T Price; H Anderson; T Iveson; T Hickish; F Lofts; A Norman Journal: J Clin Oncol Date: 2002-04-15 Impact factor: 44.544
Authors: Al B Benson; Jaffer A Ajani; Robert B Catalano; Constance Engelking; Steven M Kornblau; James A Martenson; Richard McCallum; Edith P Mitchell; Thomas M O'Dorisio; Everett E Vokes; Scott Wadler Journal: J Clin Oncol Date: 2004-07-15 Impact factor: 44.544
Authors: M Miwa; M Ura; M Nishida; N Sawada; T Ishikawa; K Mori; N Shimma; I Umeda; H Ishitsuka Journal: Eur J Cancer Date: 1998-07 Impact factor: 9.162
Authors: Simon I R Noble; Mike D Shelley; Bernadette Coles; Susan M Williams; Andrew Wilcock; Miriam J Johnson Journal: Lancet Oncol Date: 2008-06 Impact factor: 41.316
Authors: Raymond Ng; Baktiar Hasan; Nicole Mittmann; Marie Florescu; Frances A Shepherd; Keyue Ding; Charles Andrew Butts; Yvon Cormier; Gail Darling; Glenwood D Goss; Richard Inculet; Lesley Seymour; Timothy L Winton; William K Evans; Natasha B Leighl Journal: J Clin Oncol Date: 2007-06-01 Impact factor: 44.544
Authors: Y-K Kang; W-K Kang; D-B Shin; J Chen; J Xiong; J Wang; M Lichinitser; Z Guan; R Khasanov; L Zheng; M Philco-Salas; T Suarez; J Santamaria; G Forster; P I McCloud Journal: Ann Oncol Date: 2009-01-19 Impact factor: 32.976
Authors: Vincent T Janmaat; Ewout W Steyerberg; Ate van der Gaast; Ron Hj Mathijssen; Marco J Bruno; Maikel P Peppelenbosch; Ernst J Kuipers; Manon Cw Spaander Journal: Cochrane Database Syst Rev Date: 2017-11-28